Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma

Michael S. Bentz, Cynthia Cohen, Lynn R. Budgeon, Laurence M. Demers

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Comparison of one commercial immunoperoxidase kit for prostate specific acid phosphatase (PSAP) and two for prostate specific antigen (PA) with an unlabelled antibody peroxidase-antiperoxidase (PAP) technique using rabbit antihuman PSAP revealed generally good reproducibility of results on formalin fixed, paraffin-embedded sections of primary and metastatic prostatic carcinoma. Frequency of positivity was 92 per cent with both our noncommercial PAP and the kit method for PSAP, and 82 per cent and 89 per cent with kits for PA. Thus, sensitivity, with the PA kits was less than with our noncommercial PAP and the kit PSAP, with less intense immunostain and occasional false negatives. Specificity was good with all three kits, and no false positive results were obtained. Commercial immunoperoxidase kits provide a relatively easy and inexpensive means for practicing pathologists in a service-oriented setting to make more precise diagnoses in cases of poorly differentiated or metastatic carcinoma of prostatic origin.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
JournalUrology
Volume23
Issue number1
DOIs
StatePublished - Jan 1984

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma'. Together they form a unique fingerprint.

Cite this